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Abstract
Rationale—Repeated withdrawals from chronic forced ethanol exposure sensitize animals to
withdrawal-induced deficits in social interaction behavior. The deficits in social interaction behavior
following withdrawal from continuous ethanol exposure can be reduced following acute treatments
with 5-HT2C antagonists or 5-HT1A agonists.
Objectives—The present study investigated whether prior treatment with these serotonergic agents
during early withdrawals in rats subjected to repeated withdrawals from ethanol exposure would
ameliorate the social interaction deficits observed following the final withdrawal.
Methods—Sprague-Dawley rats were exposed to three cycles of 5 days forced ethanol (7%, w/v),
with 2 days of control diet after the first and second cycles. Drugs were administered IP 4 h after
removal of ethanol on the first and second cycles but not the third in one group and 4.5 h after removal
of ethanol on the third cycle in another. The social interaction test was performed 5 h after removal
of ethanol on the third cycle. Drugs tested included SB-242084, a 5-HT2C antagonist; buspirone, a
5-HT1A partial agonist; WAY-100635, a 5-HT1A antagonist; ketanserin, a 5-HT2A antagonist;
ritanserin, a mixed 5-HT2A/2C antagonist; and Ro-601075, a 5-HT2C agonist.
Results—Both SB-242084 and buspirone reduced ethanol withdrawal-induced deficits in social
interaction when given either acutely 30 min before the test or at 4 h after withdrawal from the first
and second cycles. WAY-100635 and ketanserin were completely ineffective regardless of mode of
treatment. In contrast, the 5-HT2C agonist, Ro-601075, accentuated the withdrawal-induced deficit
in social interaction behavior in rats exposed to either 4.5 or 7% ethanol diet.
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Conclusions—These results support the utility of 5-HT1A agonists and 5-HT2C antagonists in
reducing anxiety-like behavior induced by ethanol withdrawal and reducing the adaptive changes
associated with repeated withdrawals.
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Introduction
Animals exposed to forced ethanol in repeated cycles show sensitization of withdrawal-induced
anxiety-like behavior (Overstreet et al. 2002). In particular, rats exposed to a low concentration
of ethanol in three cycles of 5 days exhibit reduced social interaction behavior following the
third cycle, whereas rats exposed to the same amount of ethanol continuously do not (Overstreet
et al. 2002). This sensitization of anxiety-like behavior provides support for the postulate of
Ballenger and Post (1973) that repeated withdrawals from chronic ethanol exposure contribute
to a worsening of symptoms and seizures during a lifetime of alcoholism (see also McCown
and Breese 1990).
There is increasing evidence for the involvement of serotonergic mechanisms in anxiety
associated with ethanol and diazepam withdrawal (Andrews and File 1993; File et al. 1993).
Moreover, several studies have reported changes in serotonin (5-HT) receptor subtypes in rats
following chronic treatment with alcohol (e.g. Ulrichsen 1991; Pandey et al. 1992; Overstreet
et al. 1994; Pandey and Pandey 1996). It has also been suggested that long-term excessive
alcohol consumption is toxic to serotonergic neurons because the low prolactin response to
fenfluramine, a serotonin (5-HT) releaser, is correlated with the amount of alcohol consumption
(Berggren et al. 2002; Soloff et al. 2000).
It has been previously determined that buspirone, a 5-HT1A receptor partial agonist, will reduce
the anxiety-like symptoms associated with withdrawal from ethanol (Dougherty and Gates
1990; Lal et al. 1991; File et al. 1993), but its success as a treatment in alcoholics has been
mixed (Bruno 1989; Kranzler and Meyer 1992; Malcolm et al. 1992; Tollefson et al. 1992;
Malec et al. 1996; Fawcett et al. 1999; George et al. 1999). Recently, a selective 5-HT2C
receptor antagonist, but not 5-HT1A or 5-HT3 receptor antagonists, blocked the reduction in
social interaction following withdrawal from chronic ethanol exposure (Knapp et al. 2000).
Thus, both the stimulation of 5-HT1A receptors and the blockade of 5-HT2C receptors can
ameliorate anxiety symptoms associated with ethanol withdrawal.
The present communication provides novel support for the involvement of 5-HT1A and 5-
HT2C receptors in the social interaction deficit displayed by rats following withdrawal from
forced exposure to ethanol by employing a multiple withdrawal protocol (Overstreet et al.
2002). Given that 5-HT1A agonists and 5-HT2C antagonists are able to reduce anxiety-like
behavior related to chronic ethanol exposure when given acutely before the behavioral tasks,
we tested whether these compounds would also be effective in counteracting the reduced social
interaction if given during the withdrawal periods after the first and second cycles of a three-
cycle multiple withdrawal protocol. A preliminary report of some of these results has been
given (Knapp et al. 2001).
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Sprague-Dawley rats (Charles-River, Raleigh, N.C., USA) were obtained at 160–180 g. The
animal rooms were maintained at 22°C and 40% humidity with a 12:12 light:dark cycle (lights
on from 0900 to 2100 hours). After adaptation to the laboratory for 5 days, they were
individually housed and placed on a nutritionally complete lactalbumin-dextrose diet for 3 days
(Frye et al. 1983; Moy et al. 1997). The experimental rats were exposed to a diet containing
ethanol (ED; 7%, w/v), while control rats remained on the control diet in which the dextrose
replaced the ethanol isocalorically. The control diet rats were pair fed based on the average
volume of ED consumed.
Drugs
Buspirone hydrochloride (RBI-Sigma, St Louis, Mo., USA) was the 5-HT1A partial agonist
(Stahl 1997) used in this study. The acute dose of 0.2 mg/kg and pretreatment dose of 0.6 mg/
kg were selected from previously published reports (Lal et al. 1991; File et al. 1993).
SB-242084 (gift of Glaxo-Smith-Kline, Harrow, United Kingdom), the 5-HT2C antagonist
(Kennett et al. 1997), and WAY-100635 (RBI-Sigma), a 5-HT1A antagonist (Forster et al.
1995), were given acutely at a dose of 1 mg/kg or at a pretreatment dose of 3 mg/kg; doses
were based on recently published studies (Bristow et al. 2000; Bagdy et al. 2001). In a
subsequent dose-response study rats were pretreated with 0.3, 1.0 and 3.0 mg/kg doses of
SB-242084. Ketanserin (RBI-Sigma), a 5-HT2A antagonist (Boess and Martin 1994; Bonhaus
et al. 1997), and ritanserin (RBI-Sigma), a mixed 5-HT2A/2C antagonist (Boess and Martin
1994; Bonhaus et al. 1997), were given acutely at a dose of 1 mg/kg and at a pretreatment dose
of 3 mg/kg to correspond with the doses of SB-242084. Ketanserin also has some affinity for
the 5-HT2C receptor, but it is much less than that of ritanserin (Boess and Martin 1994; Bonhaus
et al. 1997). The 5-HT2C receptor agonist Ro-601075 (gift of Roche, Basel, Switzerland),
highly selective for the 5-HT2C receptor (Kennett et al. 2000), was given at a pretreatment dose
of 0.3 mg/kg. Buspirone was dissolved in isotonic saline vehicle, while the other drugs were
suspended in 0.5% carboxymethylcellulose (CMC).
Protocol
The experiments described in this section conformed to the Laboratory Guide for the Care of
Animals and were approved by the UNC Institutional Animal Care and Use Committee.
The study consisted of five experiments that tested the efficacy of drugs that interact with 5-
HT receptor subtypes on social interaction deficits induced by ethanol withdrawal, a sixth
experiment on whether the 5-HT2C agonist would potentiate withdrawal-induced deficits in
social interaction, and a seventh experiment to determine whether the drugs and treatment
protocols influenced the social interaction behavior of rats maintained on control diet. Each of
the first five experiments consisted of at least eight rats maintained on control diet and 32 rats
maintained on ethanol diet (ED) for a total of 15 days. Those rats on ED were withdrawn from
ethanol and placed on control diet for 2 days after the fifth and tenth exposures to ethanol. Rats
maintained on ED were injected with the drugs of interest (see above) either acutely 30 min
before the social interaction test at 4.5 h after removal of the 15th ethanol exposure, or
pretreated at 4 h after removal of the fifth and tenth ethanol exposures. All the rats that did not
receive an active drug at 4.5 h after removal of the 15th ethanol exposure were injected with
the vehicle, CMC (0.5%). At approximately 30 min after injection, rats (matched for weight
and experimental treatment) were placed as pairs in the social interaction test for a 5-min
session.
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The design was altered to determine if the 5-HT2C receptor agonist would exacerbate the effects
of ethanol withdrawal on social behavior. Three groups (n=8) were maintained on control diet
for 13 days, while two groups (n=8) were maintained continuously on 4.5% ethanol diet
(ED4.5). One group from each of these two dietary exposures was given 0.3 mg/kg Ro-601075
IP on days 8 and 13 (days 5 and 10 of exposure to ethanol) of exposure to the diet. Immediately
after day 13 on the diet, two groups of control diet rats were exposed to 7% ethanol for 5 days,
a treatment that does not produce a deficit in social interaction behavior (Overstreet et al.
2002). After day 18 of exposure to the diet (5 or 15 days of exposure to ethanol), ethanol was
removed from the diet and the social interaction test was carried out between 5 and 6 h later.
This 5-h time point was selected on the basis of extensive previous experience (e.g. Knapp et
al. 1998; Moy et al. 2000; Overstreet et al. 2002). A previous study found a similar time course
of withdrawal-induced anxiety in rats repeatedly withdrawn or withdrawn only once
(Overstreet et al. 2002).
In the seventh experiment, rats were maintained on control diet throughout. After at least 7
days on the diet, the rats were subjected to either a pretreatment protocol or an acute protocol.
In the pretreatment protocol, rats were injected with the test agent twice 5 and 10 days before
being tested in the social interaction test. In the acute protocol the rats were tested in the social
interaction test 30 min after the administration of the test compound.
Social interaction test
The social interaction test was used in these studies because it can detect the anxiolytic and
anxiogenic effects of serotonergic agents (e.g. Gonzalez et al. 1998; Bristow et al. 2000; Bagdy
et al. 2001). In the present studies, pairs of rats with the same treatment were placed in the
arena and the social interactions initiated by each member of the pair were recorded during the
5-min session. The sums of the individual scores were analyzed, as recommended by File
(1980).
The social interaction test was carried out in a square open field (60×60 cm) with 16 squares
marked out on the floor. The experienced observers were blind to the treatments given the rats.
To generate an intermediate level of social interaction behavior, the rats were unfamiliar with
the open field and the lighting conditions were low. Alcohol intakes, body weights, and
treatment conditions were used to match up the rat pairs. During the 5-min session, line crosses
(by two forepaws) and time spent in social interaction (grooming, sniffing, following, crawling
over or under) were scored individually for each rat (Kampov-Polevoy et al. 2000; Overstreet
et al. 2002).
Data analysis
Statistical analyses were carried out using the GBStat software package. The data were initially
analyzed by one-way ANOVA. If the main effects were statistically significant, post hoc
analyses were performed using Tukey’s protected t-tests. Analyses were conducted separately
for time spent in social interaction behavior and number of line crosses. Because of some
concern about the most appropriate method of analysis (see Overstreet et al. 2002), the time
spent in social interaction was analyzed both for individual animals and for pairs. Although
the result of both analyses will be presented, the graphs and tables will be based on the scores
of the rat pairs.
Results
5-HT2A and 5-HT2A/2C antagonists have mixed effects on multiple withdrawal induced anxiety
As illustrated in Fig. 1, animals that were repeatedly withdrawn from chronic ethanol and
treated with vehicle showed a marked decrease in time spent in social interaction [F(5,18)
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=21.74, P<0.0001]. Groups with different letter superscripts are significantly different,
according to Tukey’s protected t-test. Only ritanserin, a mixed 5-HT2A/2C receptor antagonist,
significantly attenuated this deficit in social interaction, but only when given during the first
and second withdrawal periods (the pretreatment regimen; Fig. 1, upper panel). When the data
on individual rats were analyzed, a significant ANOVA was also obtained [F(5,42)=34.21,
P<0.0001].
Although there were significant group differences for line crossings [F(5,18)=9.92, P<0.0001
for pairs and F(5,42)= 6.61, P<0.001 for individual rats], none of the drug treatments
counteracted the reduced line crossings of the ethanol-withdrawn rats. Indeed, both ritanserin
and ketanserin reduced activity even further when given acutely during the final withdrawal
(Fig. 1, lower panel).
The acute effects of ketanserin and ritanserin on social interaction behavior in rats maintained
on control diet, summarized in Table 1, provide an explanation for their lack of counteraction
of the deficit induced by ethanol withdrawal. Both agents had suppressing effects on time spent
in social interaction and ketanserin also suppressed line crossings (Table 1). Because ketanserin
was not effective in counteracting the deficit in social interaction in the pretreatment protocol,
it was not tested in rats maintained on control diet. Ritanserin had no effect on social interaction
behavior when given to control rats 5 and 10 days prior to the social interaction test (58.5±7.1
s for four pairs compared to 54.5±4.3 s for four pairs of rats given vehicle, P>0.05).
A 5-HT2C antagonist counteracts multiple withdrawal induced anxiety
The fact that ritanserin has high affinity for both 5-HT2A and 5-HT2C receptors (Boess and
Martin 1994) suggested that a compound more selective for the 5-HT2C receptor might be
effective in counteracting anxiety when given during prior withdrawals. Indeed, when the 5-
HT2C antagonist, SB-242084, was administered either 4.5 h after the final withdrawal or 4 h
into the first and second withdrawals of the multiple withdrawal protocol, it significantly
increased time spent in social interaction [F(3,16)=24.05, P<0.0001; Fig. 2, upper panel].
Analysis of the individual data also revealed a highly significant ANOVA [F(3,30)=14.18,
P<0.0001]. Groups with different letter superscripts are significantly different, according to
Tukey’s protected t-test.
Even though SB-242084 reduced the withdrawal-induced deficit in social interaction, this 5-
HT2C antagonist did not significantly increase the reduced line crossings, with all groups
exposed to ED being significantly less active than rats exposed to control diet [F(3,12)=20.07,
P<0.0001 for pairs and F(3,30)=14.37, P<0.001 for individual rats; Fig. 2, lower panel].
Therefore, the 5-HT2C receptor antagonist had a selective effect on time spent in social
interaction.
Two pretreatments with SB-242084 5 and 10 days before the test did not alter social interaction
behavior in rats maintained continuously on control diet or ethanol diet (58±11 s for control,
56±9.4 s for control diet given SB 24084; 60±2.4 s for ethanol diet given SB-242084; P>0.05).
Neither did acute treatment with SB-242084 significantly alter time spent in social interaction
or line crosses when given to rats maintained on control diet (Table 1). Thus, under the
conditions used in these experiments SB-242084, a 5-HT2C antagonist, does not have
anxiolytic effects in control rats.
A 5-HT2C antagonist has dose-dependent effects on multiple withdrawal-induced anxiety
As illustrated in Fig. 3, upper panel, pretreatment with SB-242084 exhibited a dose-dependent
counteraction of the deficit in social interaction [F(4,17)=16.41, P<0.0001 for rat pairs and F
(4,42)=28.03, P<0.0001 for individual rats]. Only the high dose of SB-242084 significantly
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reduced the deficit in social interaction, replicating the result above (Fig. 2). Groups with
different letter superscripts are significantly different, according to Tukey’s protected t-test.
As before, the high dose of SB-242084 did not counteract the deficit in line crossings (Fig. 3,
lower panel). The significant ANOVA [F(4,17)= 24.4, P<0.0001 for pairs and F(4,42)=17.02,
P<0.0001 for individual rats] resulted because all of the ethanol-exposed rats were less active
than the rats maintained on control diet (Fig. 3, lower panel).
A 5-HT1A antagonist does not counteract multiple withdrawal induced anxiety
Testing of the effects of the 5-HT1A receptor antagonist, WAY-100635, on social interaction
behavior of multiply ethanol-withdrawn rats is illustrated in Fig. 4. A group of rats pretreated
with the 5-HT2C receptor antagonist SB-242084 is included for comparison. There were highly
significant group differences for time spent in social interaction [F(4,18)=25.23, P<0.0001 for
pairs and F(4,42)=24.75, P<0.0001 for individual rats]. Different letter superscripts indicate
which groups are significantly different, according to Tukey’s protected t-test. Only
pretreatment with the 5-HT2C receptor antagonist during the first two withdrawals induced a
significant inhibition of the withdrawal-induced deficit in social interaction during the third
withdrawal (Fig. 4, upper panel). The reduced line crossings in the rats withdrawn from ethanol
were not affected by any of the drug treatments (Fig. 4, lower panel), although there were
statistically significant differences among the groups [F(4,18)=17.04, P<0.0001 for pairs and
F(4,42)=5.81, P=0.001, for individual rats].
A 5-HT1A partial agonist counteracts multiple withdrawal-induced anxiety
Buspirone, the 5-HT1A partial receptor agonist, influenced social interaction behavior in a
manner similar to that of SB-242084, the 5-HT2C receptor antagonist. As illustrated in Fig. 5,
buspirone, whether administered acutely during the final withdrawal or during the first and
second withdrawals only, significantly decreased the withdrawal-induced deficit in social
interaction [F(3,11)=13.53, P=0.0005 for pairs and F(3,26)=7.20, P=0.013 for individual rats].
Groups with different letter superscripts are significantly different, according to Tukey’s
protected t-test. Neither of the buspirone-treated groups was significantly different from the
rats maintained on control diet, a finding that suggests a complete normalization of the behavior
(Fig. 5, upper panel). Despite this normalization of social interaction behavior, buspirone did
not significantly alter the reduced line crossings of the ethanol-withdrawn rats (Fig. 5, lower
panel). The significant group differences [F(3,11)=6.87, P=0.007 for pairs and F(3,26)=6.00,
P=0.0033, for individual rats] were consequences of all ethanol-withdrawn rats being less
active than the rats maintained on control diet.
Two pretreatments with buspirone 5 and 10 days before the test did not alter social interaction
behavior in rats maintained continuously on control diet or ethanol diet (58±11 s for control;
53±6.5 s for control diet given buspirone; 57±9.4 for ethanol diet given buspirone; P>0.05). It
was also found that buspirone given acutely did not alter either time spent in social interaction
or line crossings (Table 1). Thus, under conditions used for these experiments, buspirone did
not have either anxiolytic or sedative effects in the control rats.
A 5-HT2C agonist sensitizes withdrawal induced anxiety
Since the 5-HT2C receptor antagonist blocked the social interaction deficit induced by multiple
withdrawals, it was tested whether prior treatment with a 5-HT2C receptor agonist would affect
social interaction if given instead of the initial two withdrawals of the multiple exposure
protocol. When rats received two prior treatments of Ro-601075, a 5-HT2C agonist, before a
single 5-day exposure to ethanol and subsequent withdrawal, they exhibited significant
reductions in social interaction (Fig. 6 upper panel), like that seen with multiple withdrawals
(Fig. 1). The difference among the control diets was highly significant, both for rat pairs [F
(4,15)=9.01, P=0.0006] and for individual rats [F(4,35)=16.52, P<0.001]. Groups with
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different letter superscripts are significantly different, according to Tukey’s protected t-test.
While there were also group differences in line crossings [F(4,15)= 3.88, P=0.02 for rat pairs
and F(4,35)=4.08, P=0.016 for individual rats], only the rats exposed to 7% ethanol were
significantly different from the group maintained on control diet (Fig. 6, lower panel).
Body weight and ethanol intake—There were no significant differences in the body
weights and alcohol intakes of the different rats that were maintained on control diet or 7%
ED, as summarized in Table 2. Rats exposed to 4.5% ED drank less ethanol and gained more
weight than rats exposed to 7% ED (data not shown). Therefore, any differential behavioral
effects of the treatments cannot be explained by differences in these measures.
Discussion
Work from our laboratory demonstrated that withdrawal from chronic ethanol exposure
induces a deficit in social interaction (Knapp et al. 2000; Overstreet et al. 2002). Both
buspirone, a 5-HT1A partial receptor agonist, and SB-242084, a 5-HT2C receptor antagonist,
given during the final withdrawal of the multiple withdrawal protocol, attenuated the deficit
in social interaction induced by the ethanol withdrawal. This finding is consistent with previous
reports on withdrawal from continuous ethanol exposure (Lal et al. 1991; File et al. 1993;
Knapp et al. 2000). The fact that neither buspirone nor SB-242084 altered social interaction
behavior in rats maintained on control diet suggests that their effects in the ethanol-withdrawn
rats may result from a counteraction of serotonergic abnormalities occurring during ethanol
withdrawal.
The role of serotonin in the behavioral deficit in social interaction induced by withdrawal from
ethanol can be said to resemble its role in the anxiety-like behavior following acute fluoxetine
treatment in that both are blocked by the 5-HT2C antagonist (Fig. 2; Bagdy et al. 2001). The
increased anxiogenic effect of m-chlorophenylpiperazine during ethanol withdrawal (Wallis
et al. 1993) is consistent with the involvement of the 5-HT2C receptor during chronic ethanol
treatment. WAY-100635, a 5-HT1A antagonist, ketanserin, a 5-HT2A antagonist, and
ritanserin, a mixed 5-HT2A/2C antagonist, did not alter the social interaction deficit during the
final withdrawal. The report (Lal et al. 1993) of anxiolytic effects of mianserin, a mixed 5-
HT2A/2C receptor antagonist, in ethanol-withdrawn rats contrasts with the present findings.
Regardless, the present results indicate selectivity in the 5-HT receptor subtypes that modulate
social interaction behavior following ethanol withdrawal.
Because serotonin was implicated in anxiety-like behavior induced by withdrawal from a single
long exposure to ethanol (e.g. File et al. 1993; Knapp et al. 2000) and after the third withdrawal
of the multiple withdrawal protocol, the next goal of the present investigation was to determine
whether sensitization of the deficit in social interaction associated with multiple withdrawals
was mediated by the serotonergic system. In this case, compounds were injected during the
initial two withdrawals and the social interaction testing was performed during the final
withdrawal. Pretreatment with either the 5-HT2C receptor antagonist, SB-242084, or the 5-
HT1A partial receptor agonist, buspirone, significantly reduced the deficit in social interaction
observed after the third withdrawal of the multiple withdrawal protocol. In contrast,
pretreatment with either the 5-HT1A receptor antagonist, WAY-100635, or the 5-HT2A
receptor antagonist, ketanserin, was effective in reducing the sensitization of the deficit in
social interaction with repeated withdrawals. When the drugs were administered to rats
maintained on control diet using the same protocol, no effects on social interaction behavior
were observed. Thus, the present findings clearly support the hypothesis that adaptive changes
in 5-HT2C and 5-HT1A receptors and/or an increased serotonin release during these early
withdrawal periods contribute to the sensitized deficit in social interaction following the final
withdrawal (Overstreet et al. 2002).
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The beneficial effect of buspirone may be due to its interaction with 5-HT1A autoreceptors
(e.g. Yocca 1990), rather than to an action on postsynaptic 5-HT1A receptors, thereby
counteracting the exaggerated release of 5-HT that accompanies ethanol withdrawal (File et
al. 1993). The fact that the 5-HT1A receptor antagonist, WAY-100635, did not counteract the
reduced social interaction in ethanol-withdrawn rats is consistent with this view. A parallel
study (data not shown) was conducted with 1-(2-pyrimidinyl)-piperazine (1-PP), an active
metabolite of buspirone that may mediate some of its actions (e.g. Amano et al. 1993; Cao and
Rodgers 1997), but this compound did not modify social interaction in ethanol-withdrawn rats.
This finding supports the interpretation that buspirone’s anxiolytic-like effects are mediated
by its interaction with the 5-HT1A autoreceptor, while the 5-HT2C receptor antagonist acts
post-synaptically to induce its anxiolytic-like effects in ethanol-withdrawn rats.
A key role of 5-HT2C receptor activation in the sensitized deficit in social interaction associated
with repeated ethanol withdrawals is supported not only by the antagonism of the 5-HT2C
receptor but also by two findings with the 5-HT2C receptor agonist, Ro-601075. Rats that were
pretreated with Ro-601075 while on control or ethanol diets exhibited a reduction in social
interaction when subsequently withdrawn from ethanol (Fig. 6). Consequently, the multiple
activation of 5-HT2C receptors with Ro-601075 in the presence and absence of ethanol
produced the same adaptive change as repeated withdrawals from ethanol (Overstreet et al.
2002).
The beneficial effects of a 5-HT1A receptor agonist and a 5-HT2C receptor antagonist on the
social interaction deficits in alcohol-withdrawn rats are consistent with some of the literature
on adaptive changes in 5-HT receptor subtypes following chronic ethanol treatment. Changes
in the 5-HT2C, 5-HT2A or 5-HT1A receptors have been reported by some investigators
(Ulrichsen 1991; Pandey et al. 1992; Pandy and Pandey 1996). However, it is difficult to relate
these findings directly to the present pharmacological observations due to differences in
method and timing of ethanol treatments. Nonetheless, because of the key role the 5-HT2C and
5-HT1A receptors are playing in the multiple withdrawal adaptation to sensitize anxiety-like
behavior, changes in the levels of these serotonin receptor subtypes might be expected in the
rats with a sensitized deficit in social interaction. Future data are needed to test this view in
brain regions most likely related to the sensitization of anxiety-like behavior seen with repeated
withdrawals.
Despite buspirone and SB-242084 pretreatment during the initial two withdrawals reducing
the withdrawal-induced deficit in social interaction during the third withdrawal, neither of these
agents nor any other drug studied in this protocol was able to ameliorate the reduction in line
crossings induced by withdrawal from ethanol (Figs 1, 2, 3, 4, 5, 6). The independent control
over line crossings and social interaction behavior due to experimental manipulations (File
1980;Overstreet et al. 2002) and pharmacological challenges (this study) suggest that
independent neural mechanisms may be involved in the affective and physical withdrawal signs
in alcoholics (De Soto et al. 1989;Miller and Harris 2000). Because the drugs used in this study
preferentially counteracted the affective symptom (anxiety-like behavior), and because
affective symptoms are important risks to relapse in alcoholics (Curran et al. 2000;Strowig
2000;Driessen et al. 2001), it is possible that the agents that counteracted the social interaction
deficits in the rats may reduce relapse in alcoholics.
The present findings suggest that blockade of the 5-HT2C receptor or stimulation of the 5-
HT1A autoreceptor may offer some potential as therapeutic approaches in the treatment of acute
anxiety-like symptoms during withdrawal in the alcoholic. Use of such drugs to reduce these
symptoms during detoxification of alcoholics might prevent subsequent anxiety-like symptoms
during withdrawal from becoming worse. Presently, there are no known reports of a selective
5-HT2C receptor antagonist being used to treat alcoholics, but there have been several negative
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or mixed clinical studies on ritanserin, a mixed 5-HT2A/2C antagonist (Meert 1994; Naranjo et
al. 1995; Wiesbeck et al. 1999, 2000).
Although early clinical studies used buspirone during acute detoxification (Dougherty and
Gates 1990; Tollefson et al. 1992), more recent studies with this drug have used chronic
regimens in an attempt to prevent alcoholics from relapsing (Malec et al. 1996; Fawcett et al.
1999; George et al. 1999). The failure of these latter studies could have been predicted from
the failure of a recent preclinical study that employed chronic as well as acute buspirone
treatment (Hedlund and Wahlstrom 1999). Buspirone might be best used as an adjunct to other
drugs used in detoxification of alcoholics.
In summary, our findings demonstrate that both a 5-HT1A partial receptor agonist and a 5-
HT2C receptor antagonist can ameliorate deficits in social interaction observed following the
third withdrawal from ethanol when given during the first and second withdrawals of a multiple
withdrawal regimen. Clinical trials of these agents as anxiolytics during acute abstinence in
alcoholics seem warranted.
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Effects of 5-HT2A antagonist ketanserin and mixed 5-HT2A/2C antagonist ritanserin on social
interaction behavior of rats repeatedly withdrawn from ethanol. The values represent the mean
±SEM seconds spent in social interaction (upper panel) or line crossings (lower panel) for four
pairs per group. a acute treatment, p pretreatment
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Effects of 5-HT2C antagonist SB-242084 on social interaction behavior of rats repeatedly
withdrawn from ethanol. The values represent the mean±SEM seconds spent in social
interaction (upper panel) or line crossings (lower panel) for four to six pairs per group. a acute
treatment, p pretreatment
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Dose-dependent effects of 5-HT2C antagonist SB-242084 on social interaction behavior of rats
repeatedly withdrawn from ethanol. The values represent the mean±SEM seconds spent in
social interaction (upper panel) or line crossings (lower panel) for three to five pairs per group.
a acute treatment, p pretreatment
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Effects of 5-HT1A antagonist WAY-100635 on social interaction behavior of rats repeatedly
withdrawn from ethanol. The values represent the mean±SEM seconds spent in social
interaction (upper panel) or line crossings (lower panel) for four pairs per group. a acute
treatment, p pretreatment
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Effects of 5-HT1A partial agonist buspirone on social interaction behavior of rats repeatedly
withdrawn from ethanol. The values represent the mean±SEM seconds spent in social
interaction (upper panel) or line crossings (lower panel) for four pairs per group. a acute
treatment, p pretreatment
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Effects of 5-HT2C agonist Ro-601075 on social interaction behavior of rats exposed to control
or 4.5% ethanol diets. The values represent the mean±SEM seconds spent in social interaction
(upper panel) or line crossings (lower panel) for four pairs per group. a acute treatment, p
pretreatment
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Table 1
Effects of acute treatment of ketanserin, ritanserin, SB-242084 and buspirone on social interaction behavior in
rats maintained on control diet. The values represent the mean±SEM for four pairs of rats. F(4,18)=7.88, P<0.01,
for social interaction. F(4,15)=4.37, P=0.015, for line crossings. Groups with different letters are significantly
different, P<0.05, according to Tukey’s test
Treatment group Measure
Time spent in social interaction Line crossings
Vehicle 63.0±6.2a 232±30a
Ketanserin (1 mg/kg) 22.3±10.0b 94±35b
Ritanserin (1 mg/kg) 29.5±3.9b 174±11a,b
SB 242084 (1 mg/kg) 74.3±11.4a 258±49a
Buspirone (0.2 mg/kg) 52.5±3.9a 154±14a,b
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Table 2
Body weights and terminal ethanol intake of rats subjected to repeated withdrawals and treated with drugs
interacting with 5-HT receptor subtypes. A acute, P pretreatment, N/A not applicable
Treatment condition Initial weight (g) Final weight (g) Ethanol intakea (g/kg per day)
Control diet 198.5±2.6 296.8±3.3 N/A
Ethanol diet 197.5±2.1 294.3±4.9 11.3±0.9
ED±SB-242084 (A) 196.5±2.8 301.0±6.9 11.3±0.4
ED±SB-242084 (P) 196.7±2.7 298.6±6.8 11.2±0.7
ED±WAY-100635 (A) 199.0±4.3 304.3±10.4 10.9±1.1
ED±WAY-100635 (P) 195.4±3.1 288.3±4.6 11.4±1.4
ED±ritanserin (A) 191.4±5.1 293.8±5.7 10.8±1.5
ED±ritanserin (P) 188.4±1.8 293.8±5.7 10.8±0.5
ED±ketanserin (A) 193.2±4.1 290.3±9.2 11.4±1.4
ED±ketanserin (P) 199.7±3.0 287.1±5.1 10.8±1.5
ED±buspirone (A) 204.3±3.1 303.5±6.4 11.2±1.5
ED±buspirone (P) 203.8±2.2 311.1±5.2 12.1±0.9
F-values 1.57, NS 1.11, NS 1.00, NS
a
Values represent the means for the last 3 days of access to the ethanol diet. There were no differences in alcohol intake at other time points
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